Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

NCT04014257 is registered in ClinicalTrials.gov with Handok Inc. as lead sponsor.

NCT NCT04014257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04014257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
Lead sponsor
Handok Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2019
Completion date
January 29, 2021
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

phase 1, solid tumor, adult